ARYA Sciences Acquisition Corp VI is a SPAC sponsored by Perceptive Advisors, a healthcare-focused investment firm with over $9.5B in assets under management. The SPAC raised $86.25M in its June 2024 IPO, placing proceeds into a trust account that held approximately $91.9M as of December 2025. The SPAC has 24 months from IPO close to complete an acquisition, or it must return the money to shareholders. The SPAC focuses exclusively on life sciences and medical technology companies in North America and Europe. In December 2025, the SPAC entered into a Business Combination Agreement with Freenome Holdings, a private biotech company, though the deal has not yet closed. The sponsor model works by issuing the sponsor "Founder Shares" at nominal cost — equity that becomes valuable only if a deal closes, creating strong incentive to complete a transaction. If no deal closes, public shareholders get their $10.00/share back from trust and the Founder Shares are worthless. Perceptive Advisors has sponsored multiple prior SPACs under the ARYA Sciences brand, with a mixed track record: one notable exit via AbbVie's acquisition of Cerevel Therapeutics, but two of four completed combinations trading well below the original SPAC price, and one SPAC that liquidated without finding a target.